Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Publication
, Journal Article
Erba, HP
Published in: Leuk Res
February 2015
There is no standard of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor. One promising strategy is to combine low-intensity treatments with novel agents. Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML. This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Leuk Res
DOI
EISSN
1873-5835
Publication Date
February 2015
Volume
39
Issue
2
Start / End Page
183 / 191
Location
England
Related Subject Headings
- Quinolones
- Quinazolines
- Organophosphates
- Male
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Gemtuzumab
- Female
- Decitabine
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P. (2015). Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res, 39(2), 183–191. https://doi.org/10.1016/j.leukres.2014.11.027
Erba, Harry P. “Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.” Leuk Res 39, no. 2 (February 2015): 183–91. https://doi.org/10.1016/j.leukres.2014.11.027.
Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res. 2015 Feb;39(2):183–91.
Erba, Harry P. “Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.” Leuk Res, vol. 39, no. 2, Feb. 2015, pp. 183–91. Pubmed, doi:10.1016/j.leukres.2014.11.027.
Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res. 2015 Feb;39(2):183–191.
Published In
Leuk Res
DOI
EISSN
1873-5835
Publication Date
February 2015
Volume
39
Issue
2
Start / End Page
183 / 191
Location
England
Related Subject Headings
- Quinolones
- Quinazolines
- Organophosphates
- Male
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Gemtuzumab
- Female
- Decitabine